Tag #Inavolisib

What is the clinical significance of inavolisib's efficacy in treating Pik3ca-mutated breast cancer?

A new oral targeted therapy, inavolisib, significantly improves outcomes for patients with locally advanced or metastatic breast cancer harboring the common Pik3ca gene mutation (present in ~40% of cases). The Inavo120 clinical trial showed that combining inavolisib with palbociclib and fulvestrant substantially increased both progression-free survival and overall survival compared to palbociclib and fulvestrant alone. The FDA has already approved this combination.